Evidence map›Paper›PMID 27052600›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2016

Identification of Apolipoprotein C-I Peptides as a Potential Biomarker and its Biological Roles in Breast Cancer.

Yadong Sun, Junjie Zhang, Fei Guo, Wei Zhao, Yuxiao Zhan, Chenyu Liu, Yuxia Fan, Jiaxiang Wang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Apolipoproteins, as the carrier proteins for lipids, are involved in the development of breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yadong SunDepartment of Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Junjie ZhangDepartment of Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Fei GuoDepartment of Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Wei ZhaoDepartment of Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Yuxiao ZhanDepartment of Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Chenyu LiuDepartment of Breast, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Yuxia FanDepartment of Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Jiaxiang WangDepartment of Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
First Affiliated Hospital of Zhengzhou University · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer (BC) is one of the most common cancers and is among the main causes of death in females around the world. Although several serum biomarkers have been identified for breast cancer, due to lack of adequate sensitivity and specificity they do not adequately distinguish BC from confounding conditions. New approaches are urgently needed to improve BC detection and treatment. MATERIAL/

methodsEighty serum samples from 20 healthy individuals and 60 patients with BC (22 triple-negative breast cancer, TNBC; 38 non-triple-negative breast cancer, NTNBC) were included. Protein profiling of serum samples was analyzed using surface-enhanced laser desorption/ionization time-of-flight mass spectroscopy (SELDI-TOF-MS). Candidate biomarkers were purified by SDS-PAGE electrophoresis and identified by MALDI-TOF/TOF.

resultsThe candidate biomarker positioned at 6447.9 m/z was significantly decreased in BC patients. Moreover, the expression intensity of the candidate biomarker was weaker in the TNBC and pre-surgery group compared with the NTNBC and post-surgery group. We ultimately identified the biomarker as apolipoprotein C-I (ApoC-I). Furthermore, we found that ApoC-I peptides inhibited proliferation of human breast cancer cells in vitro and suppressed tumor growth in vivo.

conclusionsThese results suggest that ApoC-I peptides may be a potential diagnostic biomarker and therapeutic approach for BC.

Indexed as

AdultAgedAmino Acid SequenceAnimalsApolipoprotein C-IApoptosisBiomarkers, TumorBlood ProteinsBreast NeoplasmsCase-Control StudiesCell ProliferationFemaleHumansMCF-7 CellsMice, NudeMiddle AgedApolipoprotein C-IBiomarkers, TumorBlood ProteinsPeptides

Identifiers

PMID27052600
PMCPMC4827518
OpenAlexW2340990597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.